BofA notes that yesterday morning, the FDA issued a new decision determining that the shortage of Eli Lilly’s (LLY) tirzepatide was resolved. While also noting that Hims & Hers (HIMS) does not dispense tirzepatide, so yesterday morning’s decision “does not directly impact the company or its GLP-1 sales,” the analyst argues that the news “runs counter to consensus expectations and implies (all else equal) that the duration of the semaglutide compounding opportunity may be shorter than some expected.” The firm, which thinks there is “less likelihood of material upside revisions to 2025 revenue,” which also “runs counter to the substantial upside revisions” seen for Hims to date, maintains an Underperform rating on the shares.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-movingbreaking financial news Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HIMS:
- End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink
- Hims & Hers falls after FDA ends shortage of Lilly weight loss drug
- Hims & Hers falls -12.0%
- Unusually active option classes on open December 19th
- Hims & Hers initiated with an Overweight at Morgan Stanley
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
